Clinical Trial Update: Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

View source ↗

Summary

This is a completed post-marketing surveillance study assessing the safety of the DTaP-IPV-HB-PRP-T vaccine in Korea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection
• Hepatitis B

Drugs mentioned

• DTaP-IPV-HB-PRP-T vaccine (Diphtheria, Tetanus, acellular Pertussis, Inactivated Poliovirus, Hepatitis B, Haemophilus influenzae type b PRP-T vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis B, Haemophilus Influenzae Type b Immunisation | Status: COMPLETED